<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00540332</url>
  </required_header>
  <id_info>
    <org_study_id>20070201</org_study_id>
    <nct_id>NCT00540332</nct_id>
    <nct_alias>NCT00965159</nct_alias>
  </id_info>
  <brief_title>A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy</brief_title>
  <official_title>A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics and Preliminary Efficacy of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer (HNC) Receiving Postoperative Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Orphan Biovitrum</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Swedish Orphan Biovitrum</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety and tolerability of palifermin
      on the incidence of oral mucositis in subjects with locally advanced head and neck cancer
      receiving postoperative radiotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The 20070201 study was terminated based on evaluation of Palifermin solid tumor data.
  </why_stopped>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent proteinuria</measure>
    <time_frame>11 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of treatment-emergent proteinuria</measure>
    <time_frame>11 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of chronic proteinuria</measure>
    <time_frame>11 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time (days) to onset of treatment-emergent proteinuria</measure>
    <time_frame>11 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum protein-to-creatinine ratio values during the treatment period</measure>
    <time_frame>11 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile to include Systemic clearance, volume of distribution at steady state, estimated initial concentration, area under the conc-time curve, terminal half-life and mean residual time</measure>
    <time_frame>in Week 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time (days) to onset of severe Oral Mucositis WHO grade 3 or 4</measure>
    <time_frame>11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease status at End of Treatment visit</measure>
    <time_frame>11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serum anti-palifermin antibody formation</measure>
    <time_frame>11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of second primary tumors</measure>
    <time_frame>up to 10 years (Long-Term Follow-Up phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of other malignancies</measure>
    <time_frame>up to 10 years (Long-Term Follow-Up phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to 10 years (Long-Term Follow-Up phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 10 years (Long-Term Follow-Up phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and laboratory abnormalities</measure>
    <time_frame>11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence (%) and duration (days) of severe Oral Mucositis WHO grade 3 or 4</measure>
    <time_frame>11 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Approximately 17 subjects to receive palifermin. Subjects will be enrolled as follows:
PK cohort will be randomized in a 3:1 ratio [palifermin: placebo] in at least 12 subjects
Non-PK cohort will be randomized in a 1:1 ratio [palifermin: placebo] in up to 28 subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Palifermin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 23 subjects to receive palifermin. Subjects will be enrolled as follows:
PK cohort will be randomized in a 3:1 ratio [palifermin: placebo] in at least 12 subjects
Non-PK cohort will be randomized in a 1:1 ratio [palifermin: placebo] in up to 28 subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single IV dose of placebo, 3 days before the start of RT, then once weekly placebo doses at the same dose during a planned 6 week RT course.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>palifermin</intervention_name>
    <description>120μg/kg, single IV, 3 days before the start of Radiotherapy (RT), then once weekly at the same dose during a planned 6-week RT course</description>
    <arm_group_label>Palifermin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of newly diagnosed histologically confirmed squamous cell carcinoma (AJCC
             Stage II, III or IVA) involving either the oral cavity, oropharynx, hypopharynx,
             larynx and post surgical resection (R0 or R1)

          -  Candidates for postoperative RT-only treatment and scheduled to receive RT within 12
             weeks of surgery

          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2

          -  Urinary protein-creatinine ratio (random sample, spot PCR) ≤ 0.2 mg/mg

        Exclusion Criteria:

          -  Tumors of the lips, paranasal sinuses, salivary glands, or of unknown primary tumors
             and R2 resection margins

          -  Metastatic disease (M1)

          -  Presence or history of any other primary malignancy, other than curatively treated in
             situ cervical cancer, or basal cell carcinoma of the skin without evidence of disease
             for &gt; 3 years

          -  History of pancreatitis

          -  Prior radiotherapy to the site of disease

          -  Prior chemotherapy or requiring chemotherapy during treatment phase of study

          -  Prior treatment with palifermin, or other fibroblast or keratinocyte growth factors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Biovitrum AB (publ)</affiliation>
  </overall_official>
  <removed_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2007</study_first_submitted>
  <study_first_submitted_qc>October 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <last_update_submitted>February 27, 2009</last_update_submitted>
  <last_update_submitted_qc>February 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Clinical Development</name_title>
    <organization>Biovitrum AB (publ)</organization>
  </responsible_party>
  <keyword>Oncology</keyword>
  <keyword>KGF</keyword>
  <keyword>HNC</keyword>
  <keyword>head and neck</keyword>
  <keyword>oral mucositis</keyword>
  <keyword>OM</keyword>
  <keyword>proteinurea</keyword>
  <keyword>palifermin</keyword>
  <keyword>clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

